A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.
Advanced Unresectable or Metastatic Breast Cancer
DRUG: HRS-2189|DRUG: Fluvustat|DRUG: HRS-8080|DRUG: HRS-6209|DRUG: HRS-1358
AEs+SAEs, From the first drug administration to within 30 days for the last treatment dose.|Dose limited toxicity (DLT), Up to 28 days.|Maximum tolerated dose (MTD), Up to 28 days.|Recommended Phase II Dose (RP2D), Up to 28 days.|ORR (objective response rate) - Stage II (efficacy expansion), Every 8 weeks lasting about one year.
Evaluation of pharmacokinetic parameter: Cmax,ss, 2 months.|Evaluation of pharmacokinetic parameter: Tmax,ss, 2 months.|Evaluation of pharmacokinetic parameter: Cmin,ss, 2 months.|Evaluation of pharmacokinetic parameter: AUCss, 2 months.|Best Overall Response (BOR), Every 8 weeks lasting about one year.|Duration of Response (DoR), Every 8 weeks lasting about one year.|Disease Control Rate (DCR), Every 8 weeks lasting about one year.|Clinical Benefit Rate (CBR), Every 8 weeks lasting about one year.|Progression Free Survival (PFS), Every 8 weeks lasting about one year.|Changes in antibody levels in PBMCs relative to baseline, 1 month.|Evaluate the correlation between target amplification and clinical efficacy, From the first drug administration to within 30 days for the last treatment dose.|Evaluation of the correlation between gene mutations in ctDNA and clinical efficacy, as well as the mechanism of drug resistance., From the first drug administration to within 30 days for the last treatment dose.
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.